Healthpoint Biotherapeutics To Assume Smith & Nephew Name

          Healthpoint Biotherapeutics To Assume Smith & Nephew Name

PR Newswire

FORT WORTH, Texas, Sept. 25, 2013

FORT WORTH, Texas, Sept. 25, 2013 /PRNewswire/ --Healthpoint Biotherapeutics
today announced it will assume the Smith & Nephew (LSE: SN, NYSE: SNN)
corporate identity as part of its ongoing integration into the global medical
technology business. Smith & Nephew acquired Healthpoint Biotherapeutics in
December 2012.

"Assuming the Smith & Nephew name reflects the evolution of our organization
as a biotherapeutic leader now operating within a multinational organization,"
said Rob Bancroft, President of Smith & Nephew Biotherapeutics. "As well as
continuing to market our existing products such as SANTYL*, we will retain our
focus on the development and commercialization of novel, cost-effective
biopharmaceuticals for dermal repair and regeneration."

Bioactives are the fastest growing area of wound care, illustrating how
greater understanding of wound biology is driving the development of new
biopharmaceuticals designed to stimulate the body's own regenerative

Smith & Nephew Biotherapeutics' diversified product portfolio currently serves
large and growing markets that continue to expand, given current demographic
and epidemiological trends. The business is well positioned to benefit from
this market growth with its specialized sales force, strong performance of
best-in-class products, award winning educational resources and future
prospects borne of a strategically directed pipeline.

About Chronic Wounds
Most wounds proceed toward healing in a timely, organized manner; however, for
many wounds the healing process is slowed, less well organized and may even
come to a halt altogether, leading to a chronic wound. Chronic wounds are
often derivative of another illness or condition such as diabetes, obesity,
peripheral vascular disease and immobility. These wounds–including diabetic,
venous, arterial and pressure ulcers–are considered inherently
difficult-to-heal and at risk of becoming chronic due to the underlying
disease state or condition of the individual interfering with the normal
healing process. Millions of people currently suffer from these types of
wounds, and many more are likely to be affected in the future as the
prevalence of the implicated underlying disease states and conditions
continues to rise.

An estimated $5-7 billion is spent each year on the treatment of chronic
wounds in the United States alone, and these costs are increasing at annual
rate of 7-10%. Despite these expenditures and clinical efforts, many of these
wounds fail to heal in a timely manner, increasing the risk of many
undesirable consequences and complications such as local infection (including
cellulitis and abscesses), bacteremia and sepsis, pain, osteomyelitis,
dermatitis, possible malignancy, amputation and even death. The longer it
takes for a wound to heal, the greater the likelihood of complications.

The factors that cause wounds to fail to heal are still the subject on ongoing
research. However, the science is evolving rapidly and suggests new bioactive
technologies will be the next stage of innovation in turning the sometimes
elusive process of healing into a dependable reality.

About Smith & Nephew Biotherapeutics
Smith & Nephew Biotherapeutics' research and development strategy is centered
around therapeutic enzymes, biologics and next-generation cell- and
cell-matrix based therapies for the prevention and treatment of acute, chronic
and burn-related wounds. Currently marketed products include Collagenase
SANTYL* Ointment, OASIS* Wound Matrix, OASIS* Ultra Tri-Layer Matrix and
REGRANEX* (becaplermin) Gel 0.01%. Smith & Nephew is also committed to
advancing the care and treatment of wounds through support of industry leading
continuing education from THE WOUND INSTITUTE^®. To learn more about this
comprehensive and award winning educational resource, please visit

About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has around 11,000 employees and a presence in more than 90 countries.
Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member
of the FTSE100 (LSE: SN, NYSE: SNN).

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission under the
U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's
most recent annual report on Form 20-F, for a discussion of certain of these

Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Nephew's expectations. 

*Trademark of Smith & Nephew. Certain marks registered US Patent and
Trademark Office.

SOURCE Smith & Nephew

Contact: Media: Christie Teller, Smith & Nephew, Biotherapeutics,
817.916.2242; or Analyst/Investor: Phil Cowdy, +44 (0) 20 7401 7646
Press spacebar to pause and continue. Press esc to stop.